Are you lost at SCLC, a complex tumor type with several potential up-and-coming therapies including RRx-001 (nibrozetone)?
If so, read this EpicentRx-authored review entitled, “Lost at SCLC: a review of potential platinum sensitizers.”
The review focuses on five clinical-stage therapies including lead EpicentRx therapy, RRx-001, with the potential to successfully reverse the platinum resistance that so plagues the treatment of SCLC. Of all the therapies that are used in this tumor type including checkpoint inhibitors and Delta-like ligand 3 (DLL3) antibodies like IMDELLTRA (tarlatamab-dlle), platinum-based chemotherapy is the most effective — at least initially until such time as platinum resistance sets in.
At this point, it is only a matter of time before resistance to all therapies, including immunotherapy, develops and when this happens death becomes imminent. However, if an agent like RRx-001 were to chemosensitize or chemoresensitize SCLC tumors so repeated reintroduction of platinum-based chemotherapy during the treatment course suddenly became effective, it would delay mortality perhaps indefinitely and usher in a new treatment paradigm for not only small cell lung cancer, but also other tumor types like testicular, colorectal, gastric, head and neck, lung, bladder, ovary, and endometrium where platinum chemotherapy is used.
Finally, should RRx-001 ever receive approval as a platinum sensitizer, then instead of “Lost at SCLC” we would need to amend the title of the next review on this subject to, “Found at SCLC.”